BioSpace News Archive

Aprea Therapeutics, Inc. reported financial results for the three months and year ended December 31, 2022 and provided a business update.

ThermoGenesis Holdings, Inc. reported financial and operating results for the year ended December 31, 2022 and provided a corporate strategic update.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its full year 2022 audited financial results.

TC BioPharm PLC announced the closing of its previously announced public offering of 3,437,500 of its American Depositary Shares, together with Series C warrants to purchase up to 3,437,500 of its ADSs at a public offering price of $1.60 per ADS and associated Series C Warrant.

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates.

Galapagos NV (Euronext & NASDAQ: GLPG)and NovAliX today announced a strategic collaboration in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred toNovAliX, a drug discovery-focused Contract Research Organization.

FOXO Technologies Inc. (NYSEAM: FOXO) (“FOXO” or the “Company”), a leader in commercializing epigenetic biomarkers of health and aging in life insurance, today reported financial results for the full year ended December 31, 2022 and accompanying business highlights.

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2022, its recent business highlights, and a preview of select anticipated milestones.

Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, informed that the Extraordinary General Meeting of the company held on March 30, 2023 could not be held on first notice, as the required quorum was not reached.

Retractable Technologies, Inc. reports the following information relating to the year ended December 31, 2022.